Camurus AB

Camurus AB

CAMRF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$4.28B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Camurus ABCamurus AB58.7-15%1.8-

Earnings Call Q3 2026

November 5, 2026 - AI Summary

Q3 performance: strong, broad-based growth + record profitability - Revenues +28% YoY to SEK 724m (and no milestone revenue in the quarter → underlying commercial growth). - Operating result: SEK 322m (+40% YoY) with 44% margin (up ~3%). - Product sales record SEK 582m; Buvidal SEK 574m (+26% YoY) and Oczyesa SEK 8m. - Cash & balance sheet: SEK 4.4bn cash, debt-free, cash up from ~SEK 4.1bn at quarter start.
2016 guidance reaffirmed: upper-half expectations; key forecast numbers - Management reaffirmed full-year guidance, now expecting revenues in upper half of SEK 2.6–2.9bn and operating result in upper half of SEK 0.9–1.2bn. - First 9 months: revenue SEK 1.959bn, operating result SEK 783m. - EPS (diluted) Q3: SEK 4.53 vs SEK 3.24 prior year. - Next driver is commercial + near-term pipeline milestones (FDA decision + SORENTO readout).
Commercial momentum & scale-up: Buvidal is still the engine; Brixadi milestone ahead - Buvidal: growth 10% sequentially and demand aligned with “in-market” sales. - Patients on treatment: ~81,000 at quarter end (+4,000 net vs June), tracking to 100,000 by end-2027. - Growth contributions noted: Germany, Nordics access expansion, UK prison access, plus ongoing switch activity. - Australia transition (noteworthy challenge/opportunity): - Transfer from competing long-acting product began late Q3; most who want to switch expected to do so by end of year. - Estimated remaining non-Buvidal patients on competitor: ~3,000–4,000 → likely creates a Q4 boost, but timing overlap may spill into Q1 2027. - Brixadi (U.S. royalties): SEK 137m (+23% YoY). - After period: 2026 U.S. net sales passed $300m, triggering a $15m one-time milestone payment to be recognized in Q4 (opportunity for reported growth). - Management expects investments to translate into visible acceleration only after a few quarters (execution/lag).

Exclusive for Stockcircle Pro members

Sign upSign Up
$54.03

Current Fair Value

24.9% downside

Overvalued by 24.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$4.28 Billion
Enterprise Value$152.95 Million
Earnings per Share$12.42
Beta0.52
Outstanding Shares59,509,184

Return

Return on Equity15.19%ROE
Return on Assets13.38%
Return on Invested Capital18.85%

Valuation & Multiples

P/E Ratio58.66P/E Ratio
PEG146.1PEG
Price to Sales1.8Price to Sales
Price to Book Ratio0.87Price to Book Ratio
Enterprise Value to Revenue0.06
Enterprise Value to EBIT0.16
Enterprise Value to Net Income0
Total Debt to Enterprise1.49
Debt to Equity0.05Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 5, 2026
EPS
$0.45
Est. $0.37
Revenue
$72.04 M
Est. $70.09 M

Next Earnings Call

Expected Date
February 18, 2027
EPS Estimate
$0.59
Consensus analyst estimate
Revenue Estimate
$88.84 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Camurus AB

285 employees
CEO: Sven Fredrik Tiberg

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, whic...